<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJOC</journal-id><journal-title-group><journal-title>International Journal of Organic Chemistry</journal-title></journal-title-group><issn pub-type="epub">2161-4687</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijoc.2021.113008</article-id><article-id pub-id-type="publisher-id">IJOC-111211</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Synthesis, Molecular Structure, Anti-Plasmodial, Antimicrobial and Anti-Oxidant Screening of (E)-1-(Phthalazin-1-yl)-1-[(Pyridin-2-yl)Ethylidene]Hydralazine and 1-[2-(1-(pyridine-3- yl)ethylidene)hydrazinyl]phthalazine
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Angelbert</surname><given-names>F. Awantu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Godfred</surname><given-names>A. Ayimele</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean</surname><given-names>Jules K. Bankeu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Edouard</surname><given-names>A. Nantia</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Patrick</surname><given-names>V. T. Fokou</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fabrice</surname><given-names>F. Boyom</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Emmanuel</surname><given-names>N. Nfor</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bruno</surname><given-names>N. Lenta</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Silvère</surname><given-names>A. Ngouela</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff6"><addr-line>Department of Organic Chemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon</addr-line></aff><aff id="aff1"><addr-line>Department of Chemistry, The University of Bamenda, Bambili, Cameroon</addr-line></aff><aff id="aff4"><addr-line>Department of Biochemistry, University of Yaoundé I, Yaoundé, Cameroon</addr-line></aff><aff id="aff5"><addr-line>Department of Chemistry, Higher Teachers’ Training College, University of Yaoundé I, Yaoundé, Cameroon</addr-line></aff><aff id="aff3"><addr-line>Department of Biochemistry, The University of Bamenda, Bambili, Cameroon</addr-line></aff><aff id="aff2"><addr-line>Department of Chemistry, University of Buea, Buea, Cameroon</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>91</fpage><lpage>105</lpage><history><date date-type="received"><day>30,</day>	<month>July</month>	<year>2020</year></date><date date-type="rev-recd"><day>8,</day>	<month>August</month>	<year>2021</year>	</date><date date-type="accepted"><day>11,</day>	<month>August</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Two new hydralazine hydrochloride-derived Schiff bases
  :
   (E)-1-(Phthalazin-
   
  1-yl)-1-[(Pyridin-2-yl)Ethylidene]Hydralazine (PPEH), and 1-[2-(1-(pyridine-
   
  3
  -yl)ethylidene)hydrazinyl]phthalazine (PEHP), were synthesized and partially characterized by spectroscopic and crystallographic methods including IR and X-ray. The single-crystal X-ray diffraction (SCXRD) analysis of PEHP indicate
  s
   that the hydralazine moiety of both ligands possess
  es
   the exoc
  yclic C=N bond. Both, PPEH and PEHP were tested as antimicrobials and antiparasites. Just PEHP could be considered as slightly antiplasmodial and antibacterial agent. In effect, PPEH showed low antimicrobial activity against one bacterial strain with Minimum Inhibitory Concentration (MIC) value of 250 μg/ml while PEHP showed very interesting activity against 18 out of 19 bacterial strains with MIC of 31.25 
  -
   250 μg/ml compared to the standard drug, amoxicillin. PPEH and PEHP showed higher reducing activity on ferric ions compared to Vitamin C. On the other hand, both hidrazaline synthetized derivatives show
  ed
   as better reducing agents than Vitamin C on ferric ions, while again, only the PEHP show
  ed
   slightly high inhibition of lipid peroxidation using Vitamin C as standard. Regarding their catalase activity, both compounds show
  ed
   concentration dependent effect, but Vitamin C continued showing a higher stimulatory effect on the enzyme activity. Additionally, while PPEH showed less than 80% inhibition in the preliminary antiplasmodial assay and so was not considered for the dose-response studies, PEHP
   displayed an inhibition percentage of 83.60% and 50% Inhibitory Concentration (IC
  <sub>50</sub>
  ) value of 44.13 μg/mL compared to the standard drug, artemisinin and was classified as slightly active
  .
 
</p></abstract><kwd-group><kwd>Schiff Base</kwd><kwd> Hydralazine Hydrochloride</kwd><kwd> Anti-Plasmodial Activity</kwd><kwd> Antimicrobial Activity</kwd><kwd> Anti-Oxidant Activity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The number of therapeutics used worldwide to treat or manage diseases and ailments has been on a steady rise thanks to research in the domain of health. However, the need for continued research and the discovery of new therapeutics is imminent as microorganisms develop resistance to existing therapeutics when the usage is recurrent [<xref ref-type="bibr" rid="scirp.111211-ref1">1</xref>].</p><p>Schiff bases are compounds that contain the azomethine or imine (-C=N-) functional group. First reported by Hugo Schiff, they are condensation products of primary amines with carbonyl compounds [<xref ref-type="bibr" rid="scirp.111211-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref4">4</xref>]. Hydralazine (hydrazone) based Schiff bases display significant medicinal properties including antifungal activities [<xref ref-type="bibr" rid="scirp.111211-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref6">6</xref>] , antimicrobial properties [<xref ref-type="bibr" rid="scirp.111211-ref7">7</xref>] , antihypertensive agents [<xref ref-type="bibr" rid="scirp.111211-ref8">8</xref>] , carbonyl scavenger and antiapoptotic activities [<xref ref-type="bibr" rid="scirp.111211-ref9">9</xref>] and luminescence properties [<xref ref-type="bibr" rid="scirp.111211-ref10">10</xref>]. They are reportedly less toxic than hydrazines from which they are derived owing to the blockage of the amino (-NH<sub>2</sub>) group [<xref ref-type="bibr" rid="scirp.111211-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref12">12</xref>]. The molecule hydralazine (common name: apresoline) is an efficient arterial vasodilator that has frequently been used in the treatment of patients with congestive heart failure and particularly for the treatment of hypertensive disorders especially in pregnant women [<xref ref-type="bibr" rid="scirp.111211-ref8">8</xref>].</p><p>Infectious microorganisms have recently developed resistance to existing therapeutics and this situation constitutes a global health threat [<xref ref-type="bibr" rid="scirp.111211-ref13">13</xref>]. There is therefore a dire need for new antimicrobials that if introduced, will fight against these pathogens and reverse this tendency [<xref ref-type="bibr" rid="scirp.111211-ref13">13</xref>]. The discovery of new strategies to manage drug resistance, prevent the proliferation of resistant bacteria, identify new antimicrobials/new drug combinations is an effort to alleviate suffering and should be the way forward for researchers [<xref ref-type="bibr" rid="scirp.111211-ref14">14</xref>].</p><p>Malaria and bacterial infections are infectious diseases that have been identified as the most recurrent and highest cause of mortality in Cameroon and Sub-Saharan Africa [<xref ref-type="bibr" rid="scirp.111211-ref15">15</xref>]. In fact, malaria continues to be the leading cause of mortality among children and especially those below 5 years of age with an estimated 303,000 (165,000 - 450,000) deaths in 2015; the parasite being transmitted by Plasmodium falciparum in most cases. Although there has been a 60% reduction in malaria-induced deaths since 2000 (owing to the institution of control measures such as the use of Artemisinin-based combination therapies (ACTs)), the elimination of malaria has so far been impossible because of the recent emergence and spread or ACT-resistant and insecticide resistant Plasmodium falciparum parasites [<xref ref-type="bibr" rid="scirp.111211-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref17">17</xref>].</p><p>Antioxidants are molecules that delay, prevent or remove oxidative damage to target cells. Otherwise referred to as oxidative stress, oxidative damage generates free radicals; a veritable source of danger to the body. Such free radical species as hydrogen peroxides, nitric acid radical, singlet oxygen, superoxide anion radical, hydroxyl radical and various peroxides belong to a class of highly reactive molecules or highly reactive oxygen species (ROS) [<xref ref-type="bibr" rid="scirp.111211-ref18">18</xref>]. Sometimes, oxidative forces can surpass the antioxidant systems. When this happens, the cell suffers from oxidative stress which is one of the leading causes of many chronic and degenerative diseases like atherosclerosis, cancer, diabetes mellitus, neurodegenerative disorders, ischemic heart attack, aging, imuno suppression, infectious diseases and male infertility [<xref ref-type="bibr" rid="scirp.111211-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref20">20</xref>].</p><p>Cognisant of the aforementioned, development of new technologies and drugs/leads for the treatment of malaria and bacterial infections as well as new antioxidant chemotypes is an urgent priority. As our own contribution towards achieving this objective, we embarked on the syntheses of new hydralazine-derived Schiff bases and evaluated them for their antiplasmodial, antibacterial and antioxidant activity in vitro.</p></sec><sec id="s2"><title>2. Experimental</title><sec id="s2_1"><title>2.1. Materials</title><p>Hydralazine hydrochloride, 2-acetylpyridine, 2-acetylpyrazine and other solvents were purchased from commercial sources and used without further purification. All chemicals used were of reagent grade. Methanol was used as solvent all through the synthesis. Glass apparatus with standard interchangeable joint was used after being washed with concentrated sulphuric acid, distilled water and methanol. All the synthesis was carried out in a 250 mL round-bottomed flask fitted with a quick Liebig condenser where it involved refluxing. All reactions were performed on a hot plate equipped with a magnetic stirrer. Elemental analysis was performed on a VARIO EL (Heraeus) analyzer. IR spectra were obtained from a Perkin-Elmer spectrum 100-FT-IR spectrometer. <sup>1</sup>H-NMR spectra were obtained on a Varian unity plus 400 MHz instrument. <sup>13</sup>C-NMR spectra were recorded on a Bruker AV 100 MHz instrument.</p></sec><sec id="s2_2"><title>2.2. Synthesis of (E)-1-(Phthalazin-1-yl)-1-[(Pyridin-2- yl)Ethylidene]Hydralazine (PPEH)</title><p>The Schiff base was prepared by mixing equimolar amounts of reagents; 1-(pyrazin-2-yl)ethan-1-one (or 2-acetylpyrazine) (3.20 g, 0.02 mmol) and hydralazine hydrochloride (2.20 g, 0.02 mmol) with sodium acetate as a buffer in 100 mL ethanol. A reddish-brown colour was observed upon addition of 2-acetylpyrazine to the hydralazine hydrochloride after which a bright yellow precipitate was immediately formed upon addition of sodium acetate (yield = 77%). The reaction was refluxed for three hours. The synthetic route for PPEH is shown in Scheme 1.</p><p>IR (KBr, cm<sup>−1</sup>): ν 3250, 3000, 1600. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 500 MHz): 10.3 (s, 1H, N-H), 1.80 (s, 3H, H-8’), 6.94 and 8.38 (benzene hydrogens of the hydralazine moiety) ppm. <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 125 MHz): 156.4 (C-1), 17.3 (C-8’) ppm.</p></sec><sec id="s2_3"><title>2.3. Synthesis of 1-[2-(1-(pyridine-3- yl)ethylidene)hydrazinyl]phthalazine (PEHP)</title><p>PEHP was prepared by mixing equimolar amounts of reagents; 1-(pyridin-3-yl)- ethan-1-one (or 2-acetylpyridine) (3.20 g, 0.02 mmol) and hydralazine hydrochloride (2.20 g, 0.02 mmol) (2.20 g, 0.02 mmol) with sodium acetate as a buffer in 100 mL ethanol. Upon addition of 2-acetylpyridine to the hydralazine hydrochloride, a reddish-brown colour was observed after which a bright yellow precipitate was immediately formed upon addition of sodium acetate (yield = 68%). The reaction was refluxed for three hours. Scheme 2 shows the synthetic route for PEHP.</p><p>IR (KBr, cm<sup>−1</sup>): ν 3317, 1605.6, 1591.5, 1569.2, 1532.5. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 500 MHz): 10.25 (s, 1H, N-H), 1.83 (s, 3H, H-8’), 6.86 and 8. (benzene hydrogens of the hydralazine moiety) ppm. <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 125 MHz): 156.7 (C-1), 17.0 (C-8’) ppm.</p></sec><sec id="s2_4"><title>2.4. Single Crystal X-Ray Diffraction Analysis and Structure Determination of PEHP</title><p>Crystallographic data of PEHP were taken on a Gemini diffractometer (Agilent Technologies) using Mo-Kα radiation (λ = 71.073 pm), ω-scan rotation. CrysAlis Pro [<xref ref-type="bibr" rid="scirp.111211-ref21">21</xref>] was used for data including the program SCALE3 ABSPACK [<xref ref-type="bibr" rid="scirp.111211-ref22">22</xref>] for empirical absorption correction. The refinement of all non-hydrogen atoms was performed with SHELXL-97 [<xref ref-type="bibr" rid="scirp.111211-ref23">23</xref>] and structure was solved by direct methods with SHELXS-97. All non-hydrogen atoms were refined with anisotropic thermal parameters and a difference-density Fourier map was used to locate all hydrogen atoms. CCDC 1007670 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/data_request/cif (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44)1223- 336-033; or deposit@ccdc.cam.uk). The molecular graphics were done with ORTEP- 3 [<xref ref-type="bibr" rid="scirp.111211-ref24">24</xref>] and Mercury (version 3) [<xref ref-type="bibr" rid="scirp.111211-ref25">25</xref>].</p></sec><sec id="s2_5"><title>2.5. Antimicrobial Assay</title><sec id="s2_5_1"><title>2.5.1. Organisms and Growth Conditions</title><p>Microorganisms were obtained from the culture collections of the Antimicrobial and biocontrol Agents Unit at the Department of Biochemistry, University of Yaounde 1, Cameroon. Organisms were as follows: Streptococcus pneumoniae (Klein) Chester, ATCC49619, Staphylococcus aureus BAA 917, Staphylococcus aureus subsp. aureus Rosenbach, ATCC 43300, Staphylococcus aureus NR45003, Staphylococcus aureus NR46003, Staphylococcus aureus CP7625, Shigella flexineri NR518, Salmonella enterica subsp. enterica serovar AnatumNR4294, Salmonella enterica subsp. enterica serovar MuenchenNR4311, Salmonella enterica subsp. enterica, strain A36 is serovar TyphimuriumNR-13555, Pseudomonas aeruginosa NMC592, Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan ATCC 13883, Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan ATCC 700603, Klebsiella pneumonae NR41916, Escherishia coli ATCC25922, Escherishia coli ATCC35218, Enterococcus feacalis ATCC51219, Staphylococcus aureus NR46374, and Hemophyllus influenza ATCC49247. Organisms were maintained on Muller Hinton agar (MHA) (Oxoid). at 37˚C. Inocula were prepared by diluting overnight cultures in saline to 0.5 McFarland, approximately 10<sup>8</sup> cfu∙ml<sup>−1</sup>. These suspensions were further diluted with medium as required.</p></sec><sec id="s2_5_2"><title>2.5.2. Drug Susceptibility Testing Procedure</title><p>1) Stock solution preparation</p><p>Stock solution of each sample was prepared at 100 mg/mL in DMSO.</p><p>2) Antimicrobial assays</p><p>For the estimation of the antimicrobial activities of the synthesized compounds, a broth dilution method was employed for minimum inhibitory concentration (MIC) following the Clinical and Laboratory Standards Institute (CLSI) guidelines M07-A10. Each compound was tested in duplicate for MIC determination. More specifically, 50 &#181;L of Mueller Hinton broth (MHB) were introduced in a 96-well microplate respectively. 50 &#181;L of compound were added to wells of the first line. A serial twofold dilution was made by transferring 50 &#181;L of the mixture of the first wells to the next one up to the last, final concentrations varying from 250 to 7.81 &#181;g/mL. Then, 50 &#181;L of an inoculum of 1 &#215; 10<sup>6</sup> cells/mL were introduced in all the wells except those of the sterility control. The final concentration of DMSO was &lt;1%. Each plate also contained a positive control, Amoxicillin, a negative control and a blank. Plates were incubated at 37˚C for 24 hours. The lowest concentration of compound that inhibited the visible growth of a microorganism was defined as minimum inhibitory concentration (MIC).</p></sec></sec><sec id="s2_6"><title>2.6. Antioxidant Assay</title><sec id="s2_6_1"><title>2.6.1. Organ Homogenates</title><p>A 2.5-month-old male Wistar albino rat of 150 g was obtained from the Biochemistry animal house of the Faculty of Science of The University of Bamenda. They were handled according to ethical guidelines of the Cameroon National Veterinary Laboratory and were given food and water ad libitum. After sacrifice, the liver and testes were excised out, weighed and used to prepare 20% (W/V) homogenates using phosphate buffer (pH 7.4, 50 mM).</p></sec><sec id="s2_6_2"><title>2.6.2. Chemicals</title><p>Ascorbic acid and Thiobarbituric, trichloroacetic acids were gotten from Griffin and George (Wembly Middlesex, England). Methanol was purchased from Loba Chemie Pvt. Ltd. 107, Woodehouse (Mumbai, India). Other chemicals were of high quality grade.</p></sec><sec id="s2_6_3"><title>2.6.3. Evaluation of the Antioxidant Reducing Power</title><p>The antioxidant reducing power of the synthesized compounds PPEH and PEHP was evaluated using the method described by Kamtekar and collaborators in 2014 [<xref ref-type="bibr" rid="scirp.111211-ref26">26</xref>]. The standard ascorbic acid or synthesized compounds (50, 100, 150, 200, 250 and 300 &#181;g/mL) was introduced in the tube, then 0.4 mL of phosphate buffer (pH 6.6, 0.2 M) and 0.4 mL of 1% KFe(CN)<sub>6</sub> were successively added. After homogenization, the mixture was incubated at 50˚C for 20 min, then cooled, and centrifuged (3500 rpm, 10 min, 25˚C). To 1 mL of supernatant was added 1 mL of 10% trichloroacetic acid (TCA), 1 mL of distilled water and 0.2 mL of 0.1% FeCl<sub>3</sub>. After homogenization, the absorbance was measured at 593 nm using a UV-Vis spectrophotometer.</p></sec><sec id="s2_6_4"><title>2.6.4. Inhibition of Lipid Peroxidation</title><p>A volume (0.8 mL) of phosphate buffer (pH 7.4, 50 mM) and 0.1 mL of liver or testis homogenate were added to standard ascorbic acid or synthesized compounds PPEH and PEHP (50, 100, 150, 200, 250 and 300 &#181;g/mL), followed by 0.1 mL of FeSO<sub>4</sub>. After homogenization, the mixture was incubated at 37˚C for 15 min, then 1 mL of 20% TCA and 1 mL of 0.67% thiobarbituric acid (TBA), were added. The mixture was incubated at 90˚C for 10 min, cooled and centrifuged (3000 rpm, 15 min, 4˚C). The supernatant was collected and optical density read at 530 nm [<xref ref-type="bibr" rid="scirp.111211-ref27">27</xref>] and percentage inhibition (%I) of the standard and synthesized compounds computed.</p></sec><sec id="s2_6_5"><title>2.6.5. Catalase Activity</title><p>Ascorbic acid or the synthesized compounds PPEH and PEHP (50, 100, 150, 200, 250 and 300 &#181;g/mL) were introduced into test tubes containing 0.4 mL of 9% H<sub>2</sub>O<sub>2</sub> and 2.3 mL of phosphate buffer (pH 7.2, 0.1 M) and 0.4 mL of the liver or testis homogenate were added. The absorbance was recorded at 240 nm using a UV-Vis spectrophotometer at 30, 60 and 90 seconds. Catalase activity was expressed as IU/mg protein [<xref ref-type="bibr" rid="scirp.111211-ref28">28</xref>].</p></sec><sec id="s2_6_6"><title>2.6.6. Statistical Analyses</title><p>For ferric reducing power and lipid peroxidation, the fifty percent efficient (EC<sub>50</sub>)<sub> </sub>and inhibitory (IC<sub>50</sub>) concentration of the tested compound were determined. Differences between treatments were assessed by one factor ANOVA followed by the Student-Newman-Keuls test, and P values less than 0.05 were considered statistically significant. All analyses were performed using Graphpad Instat software Version 3.0.</p></sec></sec><sec id="s2_7"><title>2.7. Antiplasmodial Assay</title>SYBR Green I Based Fluorescence Assay<p>Drug sensitivity assay was carried out in 96-well microtitration plates using SYBR green I based fluorescence assay. Sorbitol-synchronized ring stage parasites, Plasmodium falciparum Dd2 (haematocrit: 3%, parasitaemia: 0.5%, 90 μl) under normal culture conditions were incubated in the presence of prediluted synthesized compounds and reference drug. The final concentration in the test plate was range from 0.781 to 100 μg/mL for synthesized compounds and 0.0078 to 1 &#181;M for artemisinin and chloroquine, in the total volume of 100 &#181;L of culture. After 72 h of incubation, SYBR Green I was added and the fluorescence was measured using a Fluoroskan Ascent multi-well plate reader with excitation and emission at 485 and 538 nm, respectively. The fluorescence counts were plotted against the logarithm of sample concentration and the 50% inhibitory concentration (IC<sub>50</sub>) was determined by analysis of dose-response curves using GraphPad Prism 5. Experiments were done in duplicate. Cut off point for antiplasmodial activity of synthesized compounds is as follows: highly active (IC<sub>50</sub> ≤ 5 μg/mL), promisingly active (5 &gt; IC<sub>50</sub> ≥ 10 μg/mL), good activity 10 &gt; IC<sub>50</sub> ≤ 20 μg/mL, moderately active (20 &lt; IC<sub>50</sub> ≤ 40 μg/mL), marginally active (40 &gt; IC<sub>50</sub> ≤ 70 μg/mL), poorly active (70 &gt; IC<sub>50</sub> ≤ 100 μg/mL) [<xref ref-type="bibr" rid="scirp.111211-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref30">30</xref>].</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><p>The condensation reaction between hydralazine hydrochloride and 1-(pyridin-3-yl) ethan-1-one afforded PPEH in moderate yield (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and that between hydralazine hydrochloride and 1-(pyrazin-3-yl)ethan-1-one afforded PEHP in moderate yield (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><sec id="s3_1"><title>3.1. Infrared Spectra</title><p>The IR spectra of PPEH and PEHP (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig4">Figure 4</xref> respectively) was taken between 4000 - 400 cm<sup>−1</sup> region. For PPEH the bands at 3250 cm<sup>−1</sup>, 3000</p><p>cm<sup>−1</sup> and 1600 cm<sup>−1</sup> correspond to the hydrogen bonded N-H stretch [<xref ref-type="bibr" rid="scirp.111211-ref31">31</xref>] , =C-H and C=N [<xref ref-type="bibr" rid="scirp.111211-ref5">5</xref>] respectively while PEHP the strong band seen at 3317 cm<sup>−1</sup> correspond to the N-H stretch [<xref ref-type="bibr" rid="scirp.111211-ref31">31</xref>]. The strong bands that appeared at 1605.6 cm<sup>−1</sup>, 1591.5 cm<sup>−1</sup>, 1569.2 cm<sup>−1</sup> and 1532.5 cm<sup>−1</sup> are due to C=C, C=N and C=N-N=C stretches [<xref ref-type="bibr" rid="scirp.111211-ref5">5</xref>] of hydrazone. This proves the presence of these functional groups in PPEH and PEHP.</p></sec><sec id="s3_2"><title>3.2. Single Crystal X-Ray Diffraction of PEHP</title><p>Single crystal X-ray diffraction analysis of PEHP (<xref ref-type="fig" rid="fig5">Figure 5</xref>) showed that it crystallizes in a new triclinic system, in the space group P-1. The crystal structure of PEHP indicated the migration of the proton from N(3) to N(4) as the ligand is formed from its reactants. This tautomeric behaviour had earlier been reported [<xref ref-type="bibr" rid="scirp.111211-ref5">5</xref>].</p></sec><sec id="s3_3"><title>3.3. Anti-Plasmodial Activity</title><p>PPEH and PEHP were tested for anti-plasmodial activity using the SYBR green I based fluorescence assay and the results are presented in <xref ref-type="table" rid="table1">Table 1</xref>. PPEH inhibited the growth of the malaria parasites with a percentage inhibition of 78.42%, lower than the 80.41% obtained with the standard treatment of malaria, Artemisinin. Likewise, PEHP inhibited the growth of the malaria parasites with a percentage inhibition of 83.60%, higher than the 80.41% obtained with Artemisinin. Considering that the percentage inhibition of PPEH in the preliminary assay was less than 80%, it was not considered for the Dose-Response studies. Meanwhile, PEHP which displayed an inhibition percentage of 83.60% and IC<sub>50</sub> value of 44.13 μg/mL was classified as slightly active compared to Artemisinin. In addition, PEHP was more sensitive than the reference drug; chloroquine. This is normal as the strain used in the assay was the chloroquine resistant strain (Dd2) of Plasmodium falciparum.</p></sec><sec id="s3_4"><title>3.4. Antimicrobial Activity</title><p>PPEH and PEHP were tested for their antimicrobial activity on 19 bacterial strains and the results are presented in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>PPEH showed activity only on one bacterial strain with MIC value of 250 &#181;g/ml against Streptococcus pneumoniae. Antimicrobial activity of a compound is very interesting if the MIC is below to 10 &#181;g/ml, interesting or moderate if 10 &lt; MIC ≤ 100 &#181;g/ml and low if MIC &gt; 100 &#181;g/ml [<xref ref-type="bibr" rid="scirp.111211-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.111211-ref30">30</xref>]. Based on above-mentioned criteria, PPEH had low antimicrobial activity. PEHP was effective (interesting activity) against 18 bacterial strains out of 19 with MIC of 31.25 - 250 &#181;g/ml except for Staphylococcus aureus NR46003. The results obtained can however serve as starting point for lead optimisation in order to generate more active lead compounds that can be developed into new antibacterial drugs.</p></sec><sec id="s3_5"><title>3.5. Antioxidant Activity</title><sec id="s3_5_1"><title>3.5.1. Ferric Reducing Powder and Lipid Peroxidation</title><p>The effects of different compounds and Vit C on reduction of ferric ions and peroxidation of lipids are presented in <xref ref-type="table" rid="table3">Table 3</xref>. PPEH and PEHP showed higher reducing activity (P &lt; 0.05) on ferric ions compared to Vitamin C. On lipid peroxidation, PPEH showed lower inhibition (P &lt; 0.05) and PEHP showed higher inhibition compared to Vitamin C.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Antiplasmodial activity of synthetic compounds</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compound</th><th align="center" valign="middle" >% Inhibition</th><th align="center" valign="middle" >IC<sub>50</sub> (μg/mL)</th></tr></thead><tr><td align="center" valign="middle" >PPEH</td><td align="center" valign="middle" >78.42</td><td align="center" valign="middle" >N.D.</td></tr><tr><td align="center" valign="middle" >PEHP</td><td align="center" valign="middle" >83.60</td><td align="center" valign="middle" >44.13</td></tr><tr><td align="center" valign="middle" >ART</td><td align="center" valign="middle" >80.41</td><td align="center" valign="middle" >18.18 nM</td></tr><tr><td align="center" valign="middle" >CQ</td><td align="center" valign="middle" >N.D.</td><td align="center" valign="middle" >449.3 nM</td></tr></tbody></table></table-wrap><p>ART = artemisinine; CQ = Chloroquine; N.D. = Not determined.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Antibacterial activities of PPEH and PEHP</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="4"  >Antimicrobial activity (MIC in &#181;g/mL)</th></tr></thead><tr><td align="center" valign="middle" >Bacterial strains, Synthetic compounds</td><td align="center" valign="middle" >PPEH</td><td align="center" valign="middle" >PEHP</td><td align="center" valign="middle" >Amoxicilin</td></tr><tr><td align="center" valign="middle" >Streptococcus pneumoniae (Klein) Chester, ATCC49619</td><td align="center" valign="middle" >250</td><td align="center" valign="middle" >31.25</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus BAA 917;</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus subsp. Aureus Rosenbach, ATCC 43300</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >&gt;64</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus NR45003</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >31.25</td><td align="center" valign="middle" >&gt;64</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus NR46003</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;64</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus CP7625</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Shigella flexineri NR518</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Salmonella enterica subsp. enterica serovar Anatum, NR4294</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >16</td></tr><tr><td align="center" valign="middle" >Salmonella enterica subsp. enterica serovar Muenchen, NR4311</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Salmonella enterica subsp. enterica, strain A36 is serovar Typhimurium, NR-13555</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >64</td></tr><tr><td align="center" valign="middle" >Pseudomonas aeruginosa NMC592</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan ATCC 13883</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Klebsiella pneumoniaesubsp. pneumoniae (Schroeter) Trevisan ATCC 700603</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Klebsiella pneumonae NR41916</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Escherishia coli ATCC25922</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Escherishia coli ATCC35218</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >&gt;</td></tr><tr><td align="center" valign="middle" >Enterococcus feacalis ATCC51219</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >250</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus NR46374</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >31.25</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Hemophyllus influenza ATCC49247</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >31.25</td><td align="center" valign="middle" >0.5</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Effects of compounds and Vit C on reduction of ferric ions and peroxidation of lipids</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Ferric reducing power EC<sub>50</sub> (&#181;g/mL)</th><th align="center" valign="middle" >Lipid peroxidation IC<sub>50</sub> (&#181;g/mL)</th></tr></thead><tr><td align="center" valign="middle" >Vit C</td><td align="center" valign="middle" >1.749 &#177; 0.001</td><td align="center" valign="middle" >1.45 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >PPEH</td><td align="center" valign="middle" >1.515 &#177; 0.015*</td><td align="center" valign="middle" >1.59 &#177; 0.01*</td></tr><tr><td align="center" valign="middle" >PEHP</td><td align="center" valign="middle" >1.221 &#177; 0.207*</td><td align="center" valign="middle" >0.99 &#177; 0.32*</td></tr></tbody></table></table-wrap><p>*P &lt; 0.05 compared to the reference Vit C, Student-Newman-Keuls test.</p></sec><sec id="s3_5_2"><title>3.5.2. Catalase Activity</title><p>The catalase activity in the presence of PPEH, PEHP and Vitamin C is depicted in <xref ref-type="fig" rid="fig6">Figure 6</xref>. Catalase activity showed concentration dependent effect in the presence of both compounds. In general, Vitamin C presented higher stimulatory effect on the enzyme activity than PPEH and PEHP.</p></sec></sec></sec><sec id="s4"><title>4. Conclusions</title><p>PPEH and PEHP were synthesized from hydralazine hydrochloride and characterized by spectroscopic methods. X-ray crystallographic data shows PEHP as possessing an exocyclic carbon-nitrogen double bond on the hydralazine moiety.</p><p>PPEH showed activity only on one bacterial strain with MIC value of 250 &#181;g/ml against Streptococcus pneumoniae. PEHP was effective (interesting activity) against 18 bacterial strains out of 19 with MIC of 31.25 - 250 &#181;g/ml except for Staphylococcus aureus NR46003.</p><p>For antioxidant activity, PPEH and PEHP showed higher reducing activity on ferric ions compared to Vitamin C. On lipid peroxidation, PPEH showed lower inhibition and PEHP showed higher inhibition compared to Vitamin C. Catalase activity showed concentration dependent effect in the presence of both compounds. In general, Vit C presented higher stimulatory effect on the enzyme activity than PPEH and PEHP.</p><p>PPEH inhibited the growth of the malaria parasites with a percentage inhibition of 78.42%, lower than the 80.41% obtained with the standard treatment of malaria, Artemisinin. Likewise, PEHP inhibited the growth of the malaria parasites with a percentage inhibition of 83.60%, higher than the 80.41% obtained with the standard treatment of malaria, Artemisinin. Considering that the percentage inhibition of PPEH in the preliminary assay was less than 80%, PPEH was not considered for the Dose-Response studies. PEHP that was considered for the Dose-Response studies displaying an inhibition percentage of 83.60% gave an IC<sub>50</sub> value of 44.13 μg/mL.</p><p>The anti-microbial, anti-oxidant and anti-plasmodial activities of these compounds are reported for the first time and the results indicate that these novel ligands can be exploited as anti-microbial, anti-plasmodial and anti-oxidant agents.</p><p>In the continuing search for therapeutics or leads with good activity, PPEH and PEHP will be subjected to other biological activity tests with the aim of giving more value to these synthetic ligands.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We thank the Department of Chemistry at the University of Buea for providing the logistics necessary to carry out the experiments, Professor Rhett Kempe of the Institute of Inorganic Chemistry, University of Bayreuth, Germany, for providing the chemicals and Professor Dr. Evamarie Hey-Hawkins of the Institute of Inorganic Chemistry, University of Leipzig, Germany, for doing the X-ray analysis.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Awantu, A.F., Ayimele, G.A., Bankeu, J.J.K., Nantia, E.A., Fokou, P.V.T., Boyom, F.F., Nfor, E.N., Lenta, B.N. and Ngouela, S.A. (2021) Synthesis, Molecular Structure, Anti-Plasmodial, Antimicrobial and Anti-Oxidant Screening of (E)-1-(Phthalazin-1-yl)-1-[(Pyridin-2-yl) Ethylidene]Hydralazine and 1-[2-(1-(pyri- dine-3-yl)ethylidene)hydrazinyl]phthalazine. International Journal of Organic Chemistry, 11, 91-105. https://doi.org/10.4236/ijoc.2021.113008</p></sec></body><back><ref-list><title>References</title><ref id="scirp.111211-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Marianne, F., Krishan, K. and Anthony, B. (2017) Review Antibiotic Resistance. Journal of Infection and Public Health, 10, 369-378. https://doi.org/10.1016/j.jiph.2016.08.007</mixed-citation></ref><ref id="scirp.111211-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cimerman, Z., Miljani&amp;cacute;, S. and Gali&amp;cacute;, N. (2000) Schiff Bases Derived from Aminopyridines as Spectrofluorimetric Analytical Reagents. Croatica Chemica Acta, 73, 81-95.</mixed-citation></ref><ref id="scirp.111211-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Schiff, H. (1864) Mittheilungen aus dem Universit&amp;auml;tslaboratorium in Pisa: Eine neue reihe organischer Basen. Justus Liebigs Annalen der Chemie, 131, 118-119. https://doi.org/10.1002/jlac.18641310113</mixed-citation></ref><ref id="scirp.111211-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dhar, D.N. and Taploo, C.L. (1982) Schiff Bases and Their Applications. Journal of Scientific and Industrial Research, 41, 501-506.</mixed-citation></ref><ref id="scirp.111211-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nfor, E.N., Husian, A., Majoumo-Mbe, F., Njah, N.N., Offiong, E.O. and Bourne, S.A. (2013) Synthesis, Crystal Structure and Antifungal Activity of Ni(II) Complex of a New Hydrazine Derived from Antihypertensive Drug Hydralazine Hydrochloride. Polyhedron, 63, 207-213. https://doi.org/10.1016/j.poly.2013.07.028</mixed-citation></ref><ref id="scirp.111211-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sultana, N., Sarfaraz, T.B., Nelofar, A. and Hussain, S.A. (2007) Potential Antibacterial Agents: Part VI—Synthesis and Structure Elucidation of Schiff Bases Derived from Hydralazine. Pakistan Journal of Scientific and Industrial Research, 50, 169-172.</mixed-citation></ref><ref id="scirp.111211-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">El-Sherif, A.A., Shoukry, M.M. and Abd-Elgawad, M.M. (2012) Synthesis, Characterization, Biological Activity and Equilibrium Studies of Metal(II) Ion Complexes with Tridentate Hydrazine Ligand Derived from Hydralazine. Spectrochemica Acta Part A: Molecular and Biomolecular Spectroscopy, 98, 307-321. https://doi.org/10.1016/j.saa.2012.08.034</mixed-citation></ref><ref id="scirp.111211-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bakale, R.P., Naik, G.N., Mangannavar, C.V., Muchchandi, I.S., Shcherbakov, I.N., Frampton, C. and Gudasi, K.B. (2014) Mixed Ligand Complex via Zinc(II)-Mediated in Situ Oxidative Heterocyclization of Hydrochloride Salt of 2-Chlorobenzaldehyde Hydralazine Hydrazone as Potential of Antihypertensive Agent. European Journal Medicinal Chemistry, 73, 38-45. https://doi.org/10.1016/j.ejmech.2013.11.037</mixed-citation></ref><ref id="scirp.111211-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bouguerne, B., Belkheiri, N., Bedos-Belval, F., Vindis, C., Uchida, K., Duran, H., Grazide, M.H., Baltas, M., Salvayre, R. and Nègre-Salvayre, A. (2011) Antiatherogenic Effect of Bisvanillyl-Hydrazone, a New Hydralazine Derivative with Antioxidant, Carbonyl Scavenger, and Antiapoptotic Properties. Antioxidant and Redox Signaling, 14, 2093-2106. https://doi.org/10.1089/ars.2010.3321</mixed-citation></ref><ref id="scirp.111211-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Burton-Pye, B.P., Heath, S.L. and Faulker, S. (2005) Synthesis and Luminescence Properties of Lanthanide Complexes Incorporating a Hydralazine-Derived Chromophore. Dalton Transactions, 7, 146-149. https://doi.org/10.1039/b413005g</mixed-citation></ref><ref id="scirp.111211-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Rollas, S. and Küükgüzel, S.G. (2007) Biological Activities of Hydrazone Derivatives. Molecules, 12, 1910-1939. https://doi.org/10.3390/12081910</mixed-citation></ref><ref id="scirp.111211-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sah, P.P.T. and Peoples, S.A. (1954) Isonicotinyl Hydrazones as Antitubercular Agents and Derivatives for Identification of Aldehydes and Ketones. Journal of American Pharmaceutical Association, 43, 513-524. https://doi.org/10.1002/jps.3030430902</mixed-citation></ref><ref id="scirp.111211-ref13"><label>13</label><mixed-citation publication-type="book" xlink:type="simple">Knobler, S.L., Lemon, S.M., Najafi, M. and Burroughs, T. (Eds.) (2003) The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. National Academies Press (US), Washington DC.</mixed-citation></ref><ref id="scirp.111211-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Piddock, L.J.V. (2017) Understanding Drug Resistance Will Improve the Treatment of Bacterial Infections. Nature Reviews Microbiology, 15, 639-640. https://doi.org/10.1038/nrmicro.2017.121</mixed-citation></ref><ref id="scirp.111211-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kuete, V. (2010) Potential of Cameroonian Plants and Derived Products against Microbial Infections: A Review. Planta Medica, 76, 1479-1491. https://doi.org/10.1055/s-0030-1250027</mixed-citation></ref><ref id="scirp.111211-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Frith, K.-A., Fogel, R., Goldring, J.P.D., Krause, R.G.E., Khati, M., Hoppe, H., et al. (2018) Towards Development of Aptamers That Specifically Bind to Lactate Dehydrogenase of Plasmodium falciparum through Epitopic Targeting. Malaria Journal, 17, Article No. 191. https://doi.org/10.1186/s12936-018-2336-z</mixed-citation></ref><ref id="scirp.111211-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Yeung, S. (2018) Malaria—Update on Antimalarial Resistance and Treatment Approaches. The Pediatric Infectious Disease Journal, 37, 367-369. https://doi.org/10.1097/INF.0000000000001887</mixed-citation></ref><ref id="scirp.111211-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Gülin, I., Oktay, M., K&amp;imath;reci, E. and Küfrev&amp;imath;o&amp;gbreve;lu, I. (2003) Screening of Antioxidant and Antimicrobial Activities of Anise (Pimpinella anisum L.) Seed Extracts. Food Chemistry, 83, 371-382. https://doi.org/10.1016/S0308-8146(03)00098-0</mixed-citation></ref><ref id="scirp.111211-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yoshikawa, T. and Naito, Y. (2002) What Is Oxidative Stress? JMAJ, 45, 271-276.</mixed-citation></ref><ref id="scirp.111211-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Arnous, A., Makris, D.P. and Kefalas, P. (2001) Effect of Principal Polyphenolic Components in Relation to Antioxidant Characteristics of Aged Red Wines. Journal of Agriculture and Food Chemistry, 49, 5736-5742. https://doi.org/10.1021/jf010827s</mixed-citation></ref><ref id="scirp.111211-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">CrysAlis Pro: Data Collection and Data Reduction Software Package. Agilent Technologies. https://www.selectscience.net/products/crysalispro/?prodID=197116</mixed-citation></ref><ref id="scirp.111211-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">(2011) CrysAlis RED, Oxford Diffraction Ltd., Version 1.171.35.11.</mixed-citation></ref><ref id="scirp.111211-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sheldrick, G.M. (2008) A Short History of SHELX. Acta Crystallographica A, 64, 112-122. https://doi.org/10.1107/S0108767307043930</mixed-citation></ref><ref id="scirp.111211-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Farrugia, L.J. (1997) ORTEP-3 for Windows—A Version of ORTEP III with a Graphical User Interface (GUI). Journal Applied Crystallography, 30, 565. https://doi.org/10.1107/S0021889897003117</mixed-citation></ref><ref id="scirp.111211-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Macrae, C.F., Bruno, I.J., Chisholm, J.A., Edgington, P.R., McCabe, P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J. and Wood, P.A. (2008) Mercury CSD 2.0—New Features for the Visualization and Investigation of Crystal Structures. Journal Applied Crystallography, 41, 466-470. https://doi.org/10.1107/S0021889807067908</mixed-citation></ref><ref id="scirp.111211-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kamtekar, S., Keer, V. and Patil, V. (2014) Estimation of Phenolic Content, Flavonoid Content, Antioxidant and Alpha Amylase Inhibitory Activity of Marketed Polyherbal Formulation. Journal of Applied Pharmaceutical Sciences, 4, 61-65.</mixed-citation></ref><ref id="scirp.111211-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Nilsson, U.A., Olsson, L.I., Carlin, G. and Bylund-Fellenius, A.C. (1989) Inhibition of Lipid Peroxidation by Spin Labels. Journal of Biological Chemistry, 264, 11131-11135. https://doi.org/10.1016/S0021-9258(18)60439-9</mixed-citation></ref><ref id="scirp.111211-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Misra, H.P. and Fridovich, I. (1972) The Generation of Superoxide Radical during the Autoxidation of Hemoglobin. Journal of Biological Chemistry, 247, 6960-6962. https://doi.org/10.1016/S0021-9258(19)44679-6</mixed-citation></ref><ref id="scirp.111211-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Singh, N., Kaushik, N.K., Mohanakrishnan, D., Tiwari, S.K. and Sahal, D. (2015) Antiplasmodialactivity of Medicinal Plants from Chhotanagpur Plateau, Jharkhand, India. Journal of Ethnopharmacology, 165, 152-162. https://doi.org/10.1016/j.jep.2015.02.038</mixed-citation></ref><ref id="scirp.111211-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Ríos, J.L. and Recio, M.C. (2005) Medicinal Plants and Antimicrobial Activity. Journal of Ethnopharmacology, 100, 80-84. https://doi.org/10.1016/j.jep.2005.04.025</mixed-citation></ref><ref id="scirp.111211-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Yong, J.N., Majoumo-Mbe, F., Samje, M. and Nfor, E.N. (2016) Synthesis, Molecular Structure and Anti-Onchocercal Studies of 1-(Phthalazin-1-(2H)-one) [(Pyridin-2-yl)ethylidene]hydrazone. International Journal of Organic Chemistry, 6, 77-84. https://doi.org/10.4236/ijoc.2016.61008</mixed-citation></ref></ref-list></back></article>